Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 20/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23649483 | 1.00 | MAP4K1 (0.43) | MAP4K1 | |
| SCHEMBL29804114 | 1.00 | MAP4K1 (0.43) | MAP4K1 | |
| SCHEMBL29804147 | 1.00 | MAP4K1 (0.43) | MAP4K1 | |
| SCHEMBL23649482 | 1.00 | MAP4K1 (0.43) | MAP4K1 | |
| SCHEMBL23667229 | 0.84 | MAP4K1 (0.45) | MAP4K1 | |
| SCHEMBL23666700 | 0.83 | MAP4K1 (0.44) | MAP4K1 | |
| SCHEMBL25442501 | 0.81 | MAP4K1 (0.31) | MAP4K1 | |
| SCHEMBL23667232 | 0.81 | MAP4K1 (0.41) | MAP4K1 | |
| SCHEMBL23667231 | 0.79 | MAP4K1 (0.46) | MAP4K1 | |
| SCHEMBL24707675 | 0.79 | MAP4K1 (0.49) | MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103475-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORP (US) | 2026-04-16 | — | — | US | disclosed |
| US-12202844-B2 | MAP4K1 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240336630-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORP (US) | 2024-10-10 | — | — | US | disclosed |
| US-12042495-B2 | MAP4K1 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240199648-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2024-06-20 | — | — | US | disclosed |
| EP-4370523-A1 | HETEROCYCLIC COMPOUNDS AS MAP4K1 INHIBITORS | Blueprint Medicines Corporation (US) | 2024-05-22 | — | — | EP | disclosed |
| CN-117940438-A | Heterocyclic compounds as MAP4K1 inhibitors | 缆图药品公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117940406-A | MAP4K1 inhibitors | 缆图药品公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-4305041-A1 | MAP4K1 INHIBITORS | Blueprint Medicines Corporation (US) | 2024-01-17 | — | — | EP | disclosed |
| CN-117295748-A | MAP4K1 inhibitors | 缆图药品公司 | 2023-12-26 | — | — | CN | disclosed |
| WO-2023288254-A1 | HETEROCYCLIC COMPOUNDS AS MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2023288254-A1 | HETEROCYCLIC COMPOUNDS AS MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2023288264-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-01-19 | — | — | WO | disclosed |
| US-11534441-B2 | MAP4K1 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2022-12-27 | — | — | US | disclosed |
| US-11534441-B2 | MAP4K1 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2022-12-27 | — | — | US | disclosed |
| US-20220323438-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2022-10-13 | — | — | US | disclosed |
| WO-2022192145-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022192145-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2022-09-15 | — | — | WO | disclosed |
| WO-2021146370-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2021-07-22 | — | — | WO | disclosed |
| WO-2021146370-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2021-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11534441-B2 | MAP4K1 inhibitors | MAP4K1, MAP4K4, MAP4K2 | MAP4K1 1/4885 |
| US-12202844-B2 | MAP4K1 inhibitors | MAP4K1, MAP4K4, MAP4K2 | MAP4K1 1/4885 |
| US-20240336630-A1 | MAP4K1 INHIBITORS | MAP4K1, MAP4K4, MAP4K2 | MAP4K1 1/4885 |
| US-20220323438-A1 | MAP4K1 INHIBITORS | MAP4K1, MAP4K4, MAP4K2 | MAP4K1 1/4885 |
| US-20240199648-A1 | MAP4K1 INHIBITORS | MAP4K1, MAP4K4, MAP4K2 | MAP4K1 1/4885 |
| US-20260103475-A1 | MAP4K1 INHIBITORS | MAP4K1, MAP3K4, MAP4K4 | MAP4K1 1/4885 |
| US-12042495-B2 | MAP4K1 inhibitors | MAP4K1, MAP4K4, MAP4K2 | MAP4K1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.